Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT02621021
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02489266
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02390739
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
- Conditions
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT02280811
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2018-08-21
- Target Recruit Count
- 41
- Registration Number
- NCT02265809
- Locations
- π¬π§
Wellcome Trust Clinical Research Facility, Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT02153905
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT02133196
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT02111850
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT02111863
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT02062359
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.